Company Filing History:
Years Active: 2019-2021
Title: Innovations by Alexander Mark Depaoli
Introduction
Alexander Mark Depaoli is a notable inventor based in Santa Barbara, California. He has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of bile acid-related disorders. With a total of 2 patents, his work is paving the way for advancements in medical treatments.
Latest Patents
Depaoli's latest patents focus on methods for the treatment of bile acid-related disorders and the prediction of clinical sensitivity to these treatments. One of his key innovations involves the use of 7α-hydroxy-4-cholesten-3-one (C4) to predict clinical sensitivity to treatment. This method utilizes treatment peptides, including variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences, as well as fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins. These innovations aim to enhance the effectiveness of treatments for bile acid-related disorders.
Career Highlights
Alexander Mark Depaoli is currently employed at NGM Biopharmaceuticals, Inc., where he continues to develop innovative solutions in the biopharmaceutical sector. His expertise and research are instrumental in advancing the understanding and treatment of complex medical conditions.
Collaborations
Depaoli collaborates with esteemed colleagues, including Jian Luo and Hui Tian, to further enhance the research and development efforts at NGM Biopharmaceuticals, Inc. Their combined expertise contributes to the innovative environment of the company.
Conclusion
Alexander Mark Depaoli's contributions to the field of biopharmaceuticals are significant, particularly in the treatment of bile acid-related disorders. His innovative methods and collaborative efforts are shaping the future of medical treatments.